Evidence map›Paper›PMID 32753897›Full record

ArticleOncoTargets and therapy2020

ARPP-19 Mediates Herceptin Resistance via Regulation of CD44 in Gastric Cancer.

Xiang Gao, Changwen Lu, Changyu Chen, Kang Sun, Qixin Liang, Jianfeng Shuai, Xiaoming Wang, Yuxing Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiang Gao *Department of General Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, People's Republic of China.ORCID 0000-0002-9267-7590
Changwen Lu *Department of General Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, People's Republic of China.
Changyu ChenDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.ORCID 0000-0001-8888-1161
Kang SunDepartment of General Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, People's Republic of China.
Qixin LiangDepartment of General Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, People's Republic of China.ORCID 0000-0001-8213-0439
Jianfeng ShuaiDepartment of General Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, People's Republic of China.
Xiaoming WangDepartment of General Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, People's Republic of China.
Yuxing XuDepartment of General Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, People's Republic of China.ORCID 0000-0001-9482-9722
Anhui University of Traditional Chinese Medicine · CNNanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAs the first-line drug for treatment of

methodsQuantitative real-time polymerase chain reaction was performed to detect the mRNA levels of

resultsWe observed

conclusionWe have demonstrated that

Indexed as

ARPP-19CD44gastric cancerHER2Herceptin resistance

Identifiers

PMID32753897
PMCPMC7354958
OpenAlexW3040455163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.